Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $174,700.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 2,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $87.35, for a total value of $174,700.00. Following the completion of the sale, the insider owned 51,542 shares of the company’s stock, valued at $4,502,193.70. This represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Noah Goodman also recently made the following trade(s):

• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $85.05 on Monday. Kymera Therapeutics, Inc. has a twelve month low of $22.05 and a twelve month high of $103.00. The stock has a market capitalization of $6.94 billion, a price-to-earnings ratio of -23.11 and a beta of 2.28. The stock has a fifty day simple moving average of $82.95 and a two-hundred day simple moving average of $73.56.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the company posted ($0.88) earnings per share. Kymera Therapeutics’s quarterly revenue was down 60.8% compared to the same quarter last year. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. increased its position in Kymera Therapeutics by 21,538.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company’s stock valued at $1,987,000 after buying an additional 25,415 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics during the 4th quarter valued at about $198,000. Virtu Financial LLC acquired a new position in Kymera Therapeutics during the 4th quarter valued at about $2,123,000. T. Rowe Price Investment Management Inc. increased its position in Kymera Therapeutics by 3.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock valued at $49,001,000 after buying an additional 18,524 shares in the last quarter. Finally, Invesco Ltd. increased its position in Kymera Therapeutics by 46.3% during the 4th quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock valued at $9,084,000 after buying an additional 36,940 shares in the last quarter.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent research reports. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. BTIG Research reduced their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Barclays boosted their price target on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 27th. B. Riley Financial boosted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.